Pruritus - Pipeline Insight, 2024

This “Pruritus - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pruritus Understanding

Pruritus: Overview

Pruritus or itching is an unpleasant feeling that causes a desire to scratch, which negatively affects psychological and physical aspects of the life . It is the most common symptom of skin diseases, sometimes trifling or light and sometimes intolerable. It is also the most common reasons for patient to consult dermatologist . The pruritus may exist continuously or occur intermittently. Its site may be local or generalized. Itching is primarily associated with the free teleneuron which distributes in the superficial layers of the epidermis. The most of itching-related skin diseases are contact dermatitis, eczema, urticaria, neurodermatitis, prurigo, and cutaneous pruritus . In addition, the pruritus may emerge from systemic diseases including inflammatory diseases, metabolic diseases, infection, neurologic disorders, endocrine diseases, psychiatric disorders, and cancer.

Pruritus - Pipeline Insight, 2021 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve Sarcopenia.

Pruritus Emerging Drugs Chapters

This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pruritus Emerging Drugs

Linerixibat: GlaxoSmithKlineLinerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC and it is not currently approved for use anywhere in the world. In 2019, FDA granted orphan drug designation for linerixibat in the treatment of PBC and associated cholestatic pruritus. Linerixibat is a minimally absorbed small molecule inhibitor of IBAT administered as an oral tablet. By blocking resorption of bile acids in the small intestine, linerixibat reduces pruritic bile acids in circulation. Currently it is being evaluated in Phase III clinical trial to treat patients with pruritus.

Nemolizumab: GaldermaNemolizumab is a first-in-class monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from neuroimmune cytokine IL-31. IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis. With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is a central mediator that serves as the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 - worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under Phase II/III clinical development for the treatment of Pruritus. Nemolizumab was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.

CM310: Keymed BiosciencesCM310 recombinant humanized monoclonal antibody injection (referred to as CM310 herein thereafter) is an innovative humanized monoclonal antibody self-developed by Keymed Bioscience (Chengdu) Co., Ltd. targeting human IL-4 receptor alpha subunit (IL-4Ra). CM310 can selectively combine with IL-4Ra to block out the combination of IL-4Ra and IL-4 as well as IL-13, thus suppressing its bioactivity. It is currently being investigated in Phase II stage of development for the treatment of Chronic Pruritus of Unknown Origin.

EP547: Escient PharmaceuticalsEP547 is a potent, highly selective small molecule antagonist of MrgprX4, a receptor expressed on sensory itch neurons in the skin that is activated by multiple itch-inducing metabolites (pruritogens) including bile acids, bilirubin and related heme metabolites. These pruritogens can be markedly elevated in many chronic liver and kidney diseases. By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus. The drug is being investigated in Phase II clinical trial to treat patients with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis.

Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pruritus

There are approx. 25+ key companies which are developing the therapies for Pruritus. The companies which have their Pruritus drug candidates in the mid to advanced stage, i.e. Phase III include, GlaxoSmithKline.

Phases

This report covers around 27+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-Stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptide
• Antibiotics
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.

Pruritus Report Insights

• Pruritus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pruritus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pruritus drugs?
• How many Pruritus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pruritus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pruritus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• Keymed Bioscience
• Galderma
• Trevi Therapeutics
• Kiniksa Pharmaceuticals
• Avior
• MC2 therapeutics
• Regenron/ Sanofi
• AOBiome LLC
• Pfizer
• Lumosa Therapeutics
• Jiangsu HengRui Medicine
• Escient Pharmaceuticals
• Asana BioSciences
• Clexio Bioscineces
• Forte Biosciences
• Evax AG
• BioMimetix
• Mirium Pharma
• Vanda Pharmaceuticals
• Titan Pharmaceuticals
• Hepagene Therapeutics
• Tioga Pharmaceuticals
• MC2 Therapeutics
• Teikoku Pharma

Key Products

• Linerixibat
• HSK21542
• Nemolizumab
• Nalbuphine
• Vixarelimab
• AV104
• Dupilumab
• B244
• Abrocitinib
• LT5001
• SHR0410
• EP547
• ASN008
• CLE-400
• BMX-010
• FB-401

Research programme: anti-pruritus therapeutics- Tradipitant

• TP 2021
• HPG-9399
• A277

This product will be delivered within 1-3 business days.